The National Drug Code (NDC) for Bausch + Lomb's Miebo is a unique identifier used in the United States for drugs. For Miebo, the NDC can vary depending on the specific product formulation and packaging size.
What is the NDC for Miebo?
The NDC for Miebo is a three-segment number that identifies the labeler, product, and package. For example, a specific NDC for Miebo could be structured as 68676-100-10. This NDC identifies Bausch + Lomb as the labeler, a particular formulation and strength of Miebo as the product, and a specific package size. It is important to note that NDCs are assigned by the manufacturer and can change.
Where can I find the Miebo NDC?
The NDC for Miebo can typically be found on the drug's packaging, specifically on the outer carton and sometimes on the vial or bottle itself. It is also often listed in pharmacy databases and on drug information websites.
Why do different Miebo products have different NDCs?
Different formulations or strengths of Miebo would be assigned distinct NDCs. Additionally, different packaging configurations, such as the number of units in a box or the size of a vial, will also have unique NDC numbers. This system ensures precise identification for billing, inventory management, and regulatory purposes.
How does Miebo work?
Miebo (perfluorohexyloctane) is a prescription eye drop used to treat the signs and symptoms of dry eye disease. It works by reducing the evaporation of tears. Miebo is designed to spread evenly across the ocular surface, stabilizing the lipid layer of the tear film. This helps to prevent excessive water loss from the eye's surface, thereby alleviating dry eye symptoms [1].
When was Miebo approved?
Miebo was approved by the U.S. Food and Drug Administration (FDA) in May 2023 [2].
What are the side effects of Miebo?
The most common side effect reported with Miebo use is eye irritation [1].
How does Miebo compare to other dry eye treatments?
Miebo differentiates itself from many other dry eye treatments by directly targeting the lipid layer of the tear film to reduce tear evaporation, rather than solely increasing tear production or acting as a lubricant. This mechanism can be particularly beneficial for individuals whose dry eye is primarily caused by evaporative dry eye.
Are there any clinical trials for Miebo?
Yes, the efficacy and safety of Miebo were evaluated in two multicenter, randomized, double-masked, placebo-controlled clinical trials. These trials demonstrated that Miebo significantly improved the signs and symptoms of dry eye disease [2].
Sources:
1. https://www.miebo.com/
2. https://www.fda.gov/drugs/drug-approvals/miebo-perfluorohexyloctane-ophthalmic-solution